Targeting metabotropic glutamate receptors for novel treatments of schizophrenia

Support for the N-methyl-d-aspartate receptor (NMDAR) hypofunction hypothesis of schizophrenia has led to increasing focus on restoring proper glutamatergic signaling as an approach for treatment of this devastating disease. The ability of metabotropic glutamate (mGlu) receptors to modulate glutamat...

Descripción completa

Detalles Bibliográficos
Autores principales: Maksymetz, James, Moran, Sean P., Conn, P. Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405554/
https://www.ncbi.nlm.nih.gov/pubmed/28446243
http://dx.doi.org/10.1186/s13041-017-0293-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405554/
https://www.ncbi.nlm.nih.gov/pubmed/28446243
http://dx.doi.org/10.1186/s13041-017-0293-z

Ejemplares similares